Tetramethylpyrazine alleviated cytokine synthesis and dopamine deficit and improved motor dysfunction in the mice model of Parkinson’s disease

Neurological Sciences

Volumn 35, Issue 12, 2014, Pages 1963-1967

  Zhao, Hong ^a   Xu, Mei Ling ^a   Zhang, Qi ^a   Guo, Zhao Hui ^a   Peng, Ying ^a   Qu, Zheng Yi ^a   Li, Yong Nan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Parkinson s disease; Rotarod; Tetramethylpyrazine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; INTERLEUKIN 1BETA; TETRAMETHYLPYRAZINE; TUMOR NECROSIS FACTOR ALPHA; (3AS,4S,9BS)-N-(2-(8-CYANO-1-FORMYL-2,3,3A,4,5,9B-HEXAHYDRO-1H-PYRROLO(3,2-C)QUINOLIN-4-YL)-2-METHYLPROPYL)-4,6-DIFLUOROBENZOFURAN-2-CARBOXYAMIDE; BENZOFURAN DERIVATIVE; CYTOKINE; DOPAMINE; PYRAZINE DERIVATIVE; QUINOLINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; DOPAMINE DEFICIENT MOUSE; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PERFORMANCE; SUBSTANTIA NIGRA; TASK PERFORMANCE; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; BODY EQUILIBRIUM; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXCITATORY POSTSYNAPTIC POTENTIAL; IN VITRO STUDY; METABOLISM; NERVE CELL; PARKINSONIAN DISORDERS; PATCH CLAMP TECHNIQUE; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOMOTOR PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; BENZOFURANS; CORPUS STRIATUM; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY POSTSYNAPTIC POTENTIALS; IN VITRO TECHNIQUES; MALE; MICE; NEURONS; PARKINSONIAN DISORDERS; PATCH-CLAMP TECHNIQUES; POSTURAL BALANCE; PSYCHOMOTOR PERFORMANCE; PYRAZINES; QUINOLINES; VASODILATOR AGENTS;

EID: 84911978781     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1871-9     Document Type: Article

References (19)

1. Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B (2010) Synaptic dysfunction in Parkinson’s disease. Biochem Soc Trans 38:493–497
2. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106–1117
3. Liu SJ, Zukin RS (2007) Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci 30:126–134
4. Bagetta V, Sgobio C, Pendolino V, Del Papa G, Tozzi A et al (2012) Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson’s disease. J Neurosci 32:17921–17931
5. Fan L, Wang K, Shi Z, Die J, Wang C et al (2011) Tetramethylpyrazine protects spinal cord and reduces inflammation in a rat model of spinal cord ischemia–reperfusion injury. J Vasc Surg 54:192–200
6. Wu HJ, Hao J, Wang SQ, Jin BL, Chen XB (2012) Protective effects of ligustrazine on TNF-alpha-induced endothelial dysfunction. Eur J Pharmacol 674:365–369
7. Wang DQ, Wang W, Jing FC (2007) Effects of tetramethylpyrazine on brain oxidative damage induced by intracerebral perfusion of L-DOPA in rats with Parkinson’s disease. Zhongguo Zhong Xi Yi Jie He Za Zhi 27:629–632
8. Niranjan R (2013) The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes. Mol Neurobiol 49:28–38
9. Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL (2014) Microglial TNF-alpha mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia 62:145–157
10. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50–61
11. Chung YC, Bok E, Huh SH, Park JY, Yoon SH et al (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187:6508–6517
12. Li F, Zhu S, Wu C, Yan C, Liu Y et al (2011) Neuroinflammation and cell therapy for Parkinson’s disease. Front Biosci (Schol Ed) 3:1407–1420
13. Liu J, Qiang W, Ye S (1995) Effect of tetramethylpyrazine on lymphocytes proliferation response of murine splenocytes. Hua Xi Yi Ke Da Xue Xue Bao 26:177–179
14. Che XW, Zhang Y, Wang H, Wang W (2008) Effect of ligustrazine injection on levels of interleukin-4 and interferon-gamma in patients with bronchial asthma. Chin J Integr Med 14:217–220
15. Shin JW, Moon JY, Seong JW, Song SH, Cheong YJ et al (2013) Effects of tetramethylpyrazine on microglia activation in spinal cord compression injury of mice. Am J Chin Med 41:1361–1376
16. Kao TK, Chang CY, Ou YC, Chen WY, Kuan YH et al (2013) Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats. Exp Neurol 247:188–201
17. Neve KA, Seamans JK, Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24:165–205
18. Koutsokera M, Kafkalias P, Giompres P, Kouvelas ED, Mitsacos A (2014) Expression and phosphorylation of glutamate receptor subunits and CaMKII in a mouse model of Parkinsonism. Brain Res 1549:22–31
19. Azdad K, Chavez M, Don Bischop P, Wetzelaer P, Marescau B et al (2009) Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PLoS ONE 4:e6908